SCHEMBL13208123

SCHEMBL13208123

O=C(/C=C/c1ccc(O)c(O)c1)OCC1OC(Oc2ccc(O)cc2)C(O)C(O)C1O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKCA P17252 2/20 0.67
▸ CYP19A1 P11511 2/20 0.67
▸ AKR1B1 P15121 3/20 0.61
▸ CA12 O43570 3/20 0.57
▸ CA4 P22748 3/20 0.57
▸ CA7 P43166 3/20 0.57
▸ CYP3A4 P08684 2/20 0.57
▸ TYR P14679 2/20 0.57
▸ DPP4 P27487 2/20 0.56
▸ MMP2 P08253 1/20 0.54
▸ MMP3 P08254 1/20 0.54
▸ MMP9 P14780 1/20 0.54
▸ MMP12 P39900 1/20 0.54
▸ MMP13 P45452 1/20 0.54
▸ GAA P10253 2/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ CA1 P00915 1/20 0.50
▸ CA6 P23280 1/20 0.50
▸ CA5A P35218 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27729071 1.00 PRKCA (0.67) PRKCACYP19A1AKR1B1CA12CA4
SCHEMBL29456792 1.00 PRKCA (0.67) PRKCACYP19A1AKR1B1CA12CA4
SCHEMBL30214379 1.00 PRKCA (0.67) PRKCACYP19A1AKR1B1CA12CA4
SCHEMBL29509697 0.88 PRKCA (0.65) PRKCACYP19A1AKR1B1CA12CA4
SCHEMBL27728972 0.88 PRKCA (0.54) PRKCACYP19A1AKR1B1CA12CA4
SCHEMBL30384071 0.86 AKR1B1 (0.78) PRKCACYP19A1AKR1B1CA12CA4
SCHEMBL30383254 0.86 AKR1B1 (0.78) PRKCACYP19A1AKR1B1CA12CA4
SCHEMBL28901133 0.85 PRKCA (0.72) PRKCACYP19A1AKR1B1CA12CA4
SCHEMBL28035112 0.84 PRKCA (0.75) PRKCACYP19A1AKR1B1CYP3A4DPP4
SCHEMBL28390903 0.83 PRKCA (0.68) PRKCACYP19A1AKR1B1CYP3A4DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7780997-B2 Pharmaceutically active extracts of vitex leucoxylon, a process of extracting the same and a method of treating diabetes and inflammatory diseases therewith LAILA IMPEX (IN) 2010-08-24 — — US disclosed
Send feedback